EARLY PSA RESPONSE IS AN INDEPENDENT PROGNOSTIC FACTOR IN PATIENTS WITH MCRPC TREATED WITH NEXT-GENERATION ANDROGEN PATHWAY INHIBITORS

被引：1
|
作者：
Fuerea, A. C. [1 ]
Baciarello, G. [1 ]
Massard, C. [2 ]
Sauvin, L. Albiges [3 ]
Gizzi, M. [1 ]
Terrisse, S. A. [4 ]
Di Palma, M. [1 ]
Escudier, B. [5 ]
Fizazi, K. [6 ]
Loriot, Y. [5 ]
机构：
[1] Inst Gustave Roussy, Villejuif, France
[2] Inst Gustave Roussy, SITEP, Villejuif, France
[3] Inst Gustave Roussy, Dept Med Oncol, Villejuif, France
[4] Inst Canc Res, Dept Med Oncol, Villejuif, France
[5] Inst Cancerol Gustave Roussy, Villejuif, France
[6] Inst Gustave Roussy, Dept Canc Med, Villejuif, France
来源：
ANNALS OF ONCOLOGY | 2014年 / 25卷
关键词：
D O I：
10.1093/annonc/mdu336.44
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
796P
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors
    Kwon, Minsuk
    Ku, Bo Mi
    Olsen, Steve
    Park, Sehhoon
    Lefterova, Martina
    Odegaard, Justin
    Jung, Hyun-Ae
    Sun, Jong-Mu
    Lee, Se-Hoon
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    CANCER MEDICINE, 2022, 11 (15): : 2944 - 2956
  • [32] Next generation sequencing reveals CCNE1 amplification as an independent prognostic factor for triple negative breast cancer (TNBC) patients.
    Huang, Xin
    Wu, Huanwen M.
    Zhu, Changbin
    Shao, Di
    Guo, Dan
    Zhou, Yidong
    Lin, Yan
    Chen, Chang
    Xu, Ying
    Zhao, Bin
    Song, Yu
    Lu, Tao
    Sun, Qiang
    He, Xie
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [33] PROGNOSTIC IMPACT OF SOMATIC MUTATIONS ON TIME TO FIRST TREATMENT: RESULTS OF TARGETED NEXT-GENERATION SEQUENCING IN 211 PATIENTS WITH EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA
    Cristinelli, C.
    Varettoni, M.
    Orlandi, E.
    Zibellini, S.
    Rossi, M.
    Gentile, M.
    Flospergher, E.
    Ferretti, V. V.
    Rizzo, E.
    Della Porta, M. G.
    Rattotti, S.
    Cavalloni, C.
    Bergamini, F.
    Fabbri, N.
    Galli, A.
    Arcaini, L.
    HAEMATOLOGICA, 2021, 106 (10) : 40 - 41
  • [34] Prognostic impact of somatic mutations on time to first treatment: Results of targeted next-generation sequencing in 211 patients with early stage chronic lymphocytic leukemia
    Varettoni, Marzia
    Orlandi, Ester
    Zibellini, Silvia
    Rossi, Marianna
    Gentile, Massimo
    Flospergher, Elena
    Ferretti, Virginia V.
    Rizzo, Ettore
    Della Porta, Matteo G.
    Rattotti, Sara
    Cavalloni, Chiara
    Bergamini, Fabio
    Cristinelli, Caterina
    Fabbri, Nicole
    Galli, Anna
    Arcaini, Luca
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (11) : E404 - E408
  • [35] Activation of the AKT pathway and outcomes in patients (pts) treated with or without ipatasertib (ipat) in metastatic castration-resistant prostate cancer (mCRPC): Next-generation sequencing (NGS) data from the phase III IPATential150 trial.
    Sweeney, Christopher
    Chi, Kim N.
    Bracarda, Sergio
    Sternberg, Cora N.
    Olmos, David
    Sandhu, Shahneen
    Massard, Christophe
    Matsubara, Nobuaki
    Nowicka, Malgorzata
    Bienz, Nives Selak
    Schenkel, Fanny
    Chen, Geng
    Wongchenko, Matthew J.
    Garcia, Josep
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [36] Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or androgen receptor pathway inhibitors
    Georges Gebrael
    Nicolas Sayegh
    Vinay Mathew Thomas
    Beverly Chigarira
    Nishita Tripathi
    Yeon Jung Jo
    Haoran Li
    Kamal Kant Sahu
    Ayana Srivastava
    Taylor McFarland
    Benjamin L. Maughan
    Umang Swami
    Neeraj Agarwal
    Prostate Cancer and Prostatic Diseases, 2024, 27 : 279 - 282
  • [37] Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or androgen receptor pathway inhibitors
    Gebrael, Georges
    Sayegh, Nicolas
    Thomas, Vinay Mathew
    Chigarira, Beverly
    Tripathi, Nishita
    Jo, Yeon Jung
    Li, Haoran
    Sahu, Kamal Kant
    Strivastava, Ayana
    McFarland, Taylor
    Maughan, Benjamin L.
    Swami, Umang
    Agarwal, Neeraj
    PROSTATE CANCER AND PROSTATIC DISEASES, 2024, 27 (02) : 279 - 282
  • [38] TILs are an independent prognostic factor in early-stage TNBC patients achieving pathologic complete response after neoadjuvant chemotherapy
    Dieci, Maria Vittoria
    Vernieri, Claudio
    Massa, Davide
    Nicole, Lorenzo
    Griguolo, Gaia
    Miglietta, Federica
    Vingiani, Andrea
    Lobefaro, Riccardo
    Girardi, Fabio
    Vernaci, Grazia
    Giarratano, Tommaso
    Giorgi, Carlo Alberto
    Pruneri, Giancarlo
    Fassan, Matteo
    De Braud, Filippo
    Guarneri, Valentina
    CANCER RESEARCH, 2024, 84 (09)
  • [39] Targeted next-generation sequencing reveals CDKN2A alterations as a prognostic biomarker in recurrent or metastatic head and neck squamous cell carcinoma mostly treated with immune checkpoint inhibitors
    Guo, Y.
    Xue, L.
    Tang, W.
    Zhou, J.
    Xue, J.
    Li, Q.
    Ge, X.
    Lin, F.
    Zhao, W.
    ANNALS OF ONCOLOGY, 2023, 34 : S565 - S566
  • [40] Early detection of competing resistance mutations using plasma next-generation sequencing (NGS) in patients (pts) with EGER-mutant NSCLC treated with osimertinib.
    Guibert, Nicolas Marie
    Paweletz, Cloud
    Hu, Yuebi
    Feeney, Nora B.
    Plagnol, Vincent
    Poole, Valerie
    Jones, Greg
    Oxnard, Geoffrey R.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345